NeurogesX, Inc  

(Public, OTCMKTS:NGSX)   Watch this stock  
Find more results for NASDAQ:NGSX
Mar 2 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.00 - 0.01
Open     -
Vol / Avg. 0.00/38,551.00
Mkt cap 129,628.00
P/E     -
Div/yield     -
EPS -0.98
Shares 33.33M
Beta -1.40
Inst. own 6%

Key stats and ratios

Q3 (Sep '12) 2011
Net profit margin -134.62% -430.71%
Operating margin -47.28% -340.40%
EBITD margin - -329.97%
Return on average assets -68.56% -110.01%
Return on average equity - -
Employees 35 -
CDP Score - -


2215 Bridgepointe Pkwy Ste 200
FOSTER CITY, CA 94404-5067
United States - Map
+1-302-6587581 (Phone)
+1-302-6555049 (Fax)

Website links


NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pains management therapies to address unmet medical needs. Qutenza is the Company's first commercial product, available in the United States and in certain European countries. Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions and was approved by the food and drugs administration (FDA) for the management of neuropathic pain associated with postherpetic neuralgia (PHN). Qutenza is also approved in the European Union for the treatment of peripheral neuropathic pain in non-diabetic adults. The Company's advanced drug candidate is NGX-1998. NGX-1998 is a topical liquid formulation of high concentration capsaicin that the Company is developing to treat neuropathic pain conditions.